Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
NCT01800968 on ClinicalTrials.gov · last registry update 2017-02-15
An unusually large phase 2: 300 participants, more than double the 110 typical for the stage. The sponsor logged completion for October 2015. Primary outcome, as filed: Global Ranking of Predefined Events. liraglutide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Duke University
- Sponsor type
- Other
- Enrollment
- 300
- Started
- 2013-04
- Primary completion
- 2015-10 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Global Ranking of Predefined Events
Conditions studied
Acute Heart Failure
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.